Everolimus Versus Sunitinib Prospective Evaluation in Metastatic Non–Clear Cell Renal Cell Carcinoma (ESPN): A Randomized Multicenter Phase 2 Trial

BACKGROUND: Sunitinib and everolimus are standard first-line and second-line therapies, respectively, in clear cell renal cell carcinoma (ccRCC). OBJECTIVE: To conduct a randomized phase 2 trial comparing sunitinib and everolimus in non–clear cell RCC (non-ccRCC). DESIGN, SETTING, AND PARTICIPANTS:...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Eur Urol
Autors principals: Tannir, Nizar M., Jonasch, Eric, Albiges, Laurence, Altinmakas, Emre, Ng, Chaan S., Matin, Surena F., Wang, Xuemei, Qiao, Wei, Lim, Zita Dubauskas, Tamboli, Pheroze, Rao, Priya, Sircar, Kanishka, Karam, Jose A., McDermott, David F., Wood, Christopher G., Choueiri, Toni K.
Format: Artigo
Idioma:Inglês
Publicat: 2015
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4879109/
https://ncbi.nlm.nih.gov/pubmed/26626617
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.eururo.2015.10.049
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars